Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies
Background CTLA-4 blockade with ipilimumab is Food and Drug Administration-approved for melanoma as a monotherapy and has been shown to modulate the circulating T-cell repertoire. We have previously reported clinical trials combining CTLA-4 blockade with granulocyte-macrophage colony-stimulating fac...
Salvato in:
| Autori principali: | , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMJ Publishing Group
2020-05-01
|
| Serie: | Journal for ImmunoTherapy of Cancer |
| Accesso online: | https://jitc.bmj.com/content/8/1/e000368.full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|